To investigate the effect of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), on the survival and production of nitric oxide (NO) in human trabecular meshwork cells (HTMC).
MethodsPrimarily cultured HTMC were exposed to 0, 0.25, 1.0, and 2.5 mg/ml bevacizumab for 24 hours. Cellular survival and production of NO were assessed by MTT assay and Griess assay, respectively.
ResultsBevacizumab did not affect the cellular survival at low concentrations but decreased cellular survival significantly at high concentrations (>1.0 mg/ml) accompanied with increased NO production.
ConclusionsHigh concentrations of bevacizumab may be toxic to HTMC.